Compare HTH & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HTH | AKRO |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 4.5B |
| IPO Year | 2004 | 2019 |
| Metric | HTH | AKRO |
|---|---|---|
| Price | $34.51 | $54.54 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 2 | 10 |
| Target Price | $34.00 | ★ $73.56 |
| AVG Volume (30 Days) | 365.5K | ★ 1.7M |
| Earning Date | 10-23-2025 | 11-07-2025 |
| Dividend Yield | ★ 2.09% | N/A |
| EPS Growth | ★ 53.28 | N/A |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $1,259,399,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.64 | N/A |
| P/E Ratio | $13.76 | ★ N/A |
| Revenue Growth | ★ 7.66 | N/A |
| 52 Week Low | $26.67 | $21.34 |
| 52 Week High | $36.14 | $58.40 |
| Indicator | HTH | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 55.34 | 66.54 |
| Support Level | $34.32 | $54.22 |
| Resistance Level | $35.35 | $54.70 |
| Average True Range (ATR) | 0.81 | 0.14 |
| MACD | 0.09 | -0.11 |
| Stochastic Oscillator | 70.13 | 64.18 |
Hilltop Holdings Inc is a Dallas-based financial holding company. The Company has two primary business units, PCC (banking and mortgage origination) and Securities Holdings (broker-dealer). The banking segment includes the operations of the Bank. The banking segment provides business and consumer banking services from offices located throughout Texas and generates revenue from its portfolio of earning assets. The broker-dealer segment includes the operations of Securities Holdings, which operates through its wholly owned subsidiaries Hilltop Securities, Asset Managment LLC, etc. The broker-dealer segment generates a majority of its revenues from fees and commissions earned from investment advisory and securities brokerage services. Majority of revenue is from Banking Segment.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.